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Abstract
Leucine rich repeat transmembrane protein 3 (LRRTM3) is member of a synaptic protein family. LRRTM3 is a nested gene
within a-T catenin (CTNNA3) and resides at the linkage peak for late-onset Alzheimer’s disease (LOAD) risk and plasma
amyloid b (Ab) levels. In-vitro knock-down of LRRTM3 was previously shown to decrease secreted Ab, although the
mechanism of this is unclear. In SH-SY5Y cells overexpressing APP and transiently transfected with LRRTM3 alone or with
BACE1, we showed that LRRTM3 co-localizes with both APP and BACE1 in early endosomes, where BACE1 processing of APP
occurs. Additionally, LRRTM3 co-localizes with APP in primary neuronal cultures from Tg2576 mice transduced with LRRTM3-
expressing adeno-associated virus. Moreover, LRRTM3 co-immunoprecipitates with both endogenous APP and
overexpressed BACE1, in HEK293T cells transfected with LRRTM3. SH-SY5Y cells with knock-down of LRRTM3 had lower
BACE1 and higher CTNNA3 mRNA levels, but no change in APP. Brain mRNA levels of LRRTM3 showed significant correlations
with BACE1, CTNNA3 and APP in ,400 humans, but not in LRRTM3 knock-out mice. Finally, we assessed 69 single nucleotide
polymorphisms (SNPs) within and flanking LRRTM3 in 1,567 LOADs and 2,082 controls and identified 8 SNPs within a linkage
disequilibrium block encompassing 59UTR-Intron 1 of LRRTM3 that formed multilocus genotypes (MLG) with suggestive
global association with LOAD risk (p = 0.06), and significant individual MLGs. These 8 SNPs were genotyped in an
independent series (1,258 LOADs and 718 controls) and had significant global and individual MLG associations in the
combined dataset (p = 0.02–0.05). Collectively, these results suggest that protein interactions between LRRTM3, APP and
BACE1, as well as complex associations between mRNA levels of LRRTM3, CTNNA3, APP and BACE1 in humans might
influence APP metabolism and ultimately risk of AD.
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Introduction
LRRTM3 is a member of the synaptic leucine rich repeat
transmembrane family with four highly conserved members, each
with distinct brain distributions [1]. Three LRRTMs (LRRTM1-3)
reside within introns of an a-catenin gene and are transcribed in
the direction opposite to that of their a-catenin partners [1].
LRRTM3 exists within the seventh intron of CTNNA3 (also known
as VR22), encoding a-T-catenin. Both LRRTM3 and CTNNA3 are
located at the genetic linkage peaks for plasma levels of amyloid ß
(Aß) identified by our group in extended late-onset Alzheimer’s
disease (LOAD) families [2] and for LOAD risk detected in an
independent sib-pair study [3], making both genes interesting
positional candidate LOAD risk genes.
LRRTM3 is also a functionally relevant candidate LOAD gene,
as it is structurally similar to a family of neuronal receptors that
includes the NOGO receptor, which inhibits neuronal regenera-
tion and APP processing [4]. In a high-throughput siRNA
screening of 15,200 genes by Majercak et al. [4], siRNA targeting
of LRRTM3 inhibited the secretion of Ab40, Ab42, and sAPPb in
HEK293 and SH-SY5Y cells overexpressing amyloid precursor
protein (APP), but had no effect on sAPPa or c-secretase cleavage
of the 99 amino acid C-terminal fragment of APP. Given these
results and the lack of an effect of LRRTM3 knock-down on total
BACE activity, mRNA levels of APP processing secretases, or APP
levels in that study, the authors concluded that LRRTM3
mediates BACE1 processing of APP potentially by vesicle
trafficking or signaling. Despite additional scant evidence for
promotion of APP processing by LRRTM3 [5,6], we are not
aware of any studies to date that investigate the interaction
between APP, BACE1 and LRRTM3.
There have been several genetic association studies on the
chromosome 10q linkage region harboring CTNNA3 and
LRRTM3. Our group first published a fine mapping study of this
region that investigated the effect of 51 SNPs on the intermediate
Ab phenotype; and identified two intronic SNPs (rs7070570,
rs12357560) in tight linkage disequilibrium (LD) that accounted
for the chromosome 10q Ab linkage signal in our extended
families [2], replication of the Ab association in a second
independent set of families [7] and decay of this association signal
within the large CTNNA3 genic region. These findings strongly
implicated CTNNA3 as a LOAD gene that affects Ab42.
Subsequently, there have been numerous reports of both positive
[8,9,10,11] and negative [12,13] association between CTNNA3
SNPs and AD risk, highlighting the complexity of this region [14].
LRRTM3 genetic associations with AD risk was first studied, in a
follow-up to our report on CTNNA3 by Martin et al., who assessed
11 variants in both CTNNA3 and its nested gene LRRTM3 and
identified evidence of association with AD for both genes [8]. In a
two-stage analysis assessing for heterogeneity and gene-gene
interactions in 22 candidate genes, LRRTM3 SNPs were identified
to be the most influential in determining clusters for AD risk [15].
Furthermore in this study, LRRTM3 SNP multilocus genotypes
(MLGs) were shown to have statistical interactions with PLAU,
previously implicated in AD risk and Ab levels [16], as well as
CDC2 and ACE in conferring AD risk. Additional studies identified
multilocus genotypes composed of SNPs in ACE, LRRTM3 and
A2M with significant AD risk association, where all three genes
have implications in Ab metabolism [17]. Finally, a study in
Caucasian-American and Carribean-Hispanic case-control series,
assessed 5 SNPs and identified SNP and haplotype associations
with AD risk, in especially the latter group [6]. Although,
collectively these studies implicate LRRTM3 SNPs, haplotypes or
multilocus genotypes (MLGs) in risk for LOAD, to date there have
not been any systematic fine-mapping analysis of the LRRTM3
region in LOAD.
In this study, we first aimed to characterize the intracellular,
biochemical and gene expression interactions between LRRTM3,
APP and BACE1, given the potential functional role of LRRTM3
in promoting BACE1 processing of APP [4]. Second, we aimed to
accomplish fine mapping of the LRRTM3 locus by analyzing 69
SNPs in this region in a LOAD case-control cohort (1,567 LOADs
and 2,082 controls) and by follow-up of the significant results in a
second independent series (1,258 LOADs and 718 controls). Our
findings demonstrate intracellular, biochemical and gene expres-
sion interactions between LRRTM3 and APP and BACE1 for the
first time and also identify a region in the 59UTR-Intron 1 of
LRRTM3 that has variants which associate with LOAD risk. The
gene expression studies from the in-vitro LRRTM3 knock-down
model and human brains, reveal complex correlations between
mRNA levels of LRRTM3, CTNNA3, APP and BACE1. These gene
and protein interactions may ultimately influence APP metabolism
and AD risk. These results have implications for future genetic and
functional studies of this gene and its role in AD.
Materials and Methods
Ethics Statement
All studies involving human samples were approved by the
Mayo Clinic Institutional Review Board and appropriate written,
informed consent was obtained from all participants. All mouse
studies conducted in this study were approved by the Mayo Clinic
Institutional Animal Care and Use Committee.
LRRTM3 siRNA
Anti-human LRRTM3 siRNA (si-LRRTM3) and control siRNA
(si-control; MISSIONHsiRNA) were purchased from Sigma-
Aldrich. Initially, three different LRRTM3 siRNAs were tested
(SASI_Hs02_00369484= siRNA_1, SASI_Hs01_00163674= -
siRNA_2, SASI_Hs01_00163676= siRNA_3) and given its supe-
rior knock-down effect, SASI_Hs01_00163676 was chosen for all
experiments in this study (Text S1, Figures S1–S2).
SH-SY5Y human neuroblastoma cells were stably transfected
with human wild-type APP construct (SH-SY5Y-APP695wt). The
same batch of SH-SY5Y cells were split and transfected with 50
pmols of either si-LRRTM3 or si-control with four separate
transfections per treatment group, using TransFectin lipid reagent
(BioRad) according to manufacturer’s protocols. After 24 hours,
cells and media were harvested for Western blot analysis, Ab40,
Ab42, sAPPa and sAPPb ELISA experiments.
ELISAs
Following harvesting, media from SH-SY5Y cells were submit-
ted to ELISA measurements for Ab40, Ab42, sAPPa and sAPPb.
Ab40 and Ab42 levels in the media were measured using a
sandwich ELISA system. Ab40 ELISA system used 33.1.1
antibody (epitope: Ab1–16) for capture and horse-radish perox-
idase-conjugated 13.1.1 (13.1.1-HRP; epitope: Ab35–40) as the
detection antibody. For Ab42 measurements, 2.1.3 antibody
(epitope: Ab35–42) was used for capture and 4G8-HRP
(CovanceH, epitope: Ab17–24) for detection. Apart from 4G8,
all other antibodies were originally manufactured by Mayo Clinic.
Media was diluted 1:5 in EC buffer for the Ab40 measurements,
but not for Ab42. The Ab ELISAs were done in duplicate and the
average values were used in the statistical analyses. Optical density
(OD) values for all measurements were obtained using the Softmax
program. Absolute concentrations for the samples in femtomoles
per milliliter unit were determined by comparison of their ODs to
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those of known concentrations of synthetic Ab40 and Ab42
peptides.
For endogenous mice brain Ab measurements, the Mayo
ELISA system utilizing antibodies 13.1.1 (capture) and 32.4.1-
HRP (detection Ab 1–16) were used for Ab40 and the Wako
ELISA system was used for Ab42.
For sAPPbmeasurements, the BetaMarkTM chemiluminescent
kit from CovanceH was utilized according to manufacturer’s
protocols. All samples were diluted 1:7 in EC buffer, then
measured, using single measurement per experiment. sAPPa was
measured using a commercial ELISA from IBLH per manufac-
turer’s instructions and as duplicates, using 1:15 dilution in EC
buffer.
For all ELISAs, si-LRRTM3 and si-control treated groups were
assayed in a single batch and on the same ELISA plate. Each
experiment was repeated at least one additional time.
Non-parametric Mann-Whitney test was used to assess signif-
icance of difference in results between si-LRRTM3 and si-control
treated samples, using StatsDirect 2.7.8.
Western Blot Analysis
Protein was extracted from harvested cells using Lysis Buffer
(150mM NaCl, 50mM Tris pH 7.5, 0.1% Triton). After detection
of the total protein concentration using Thermo BCA protein
assay, equal amounts of protein for each treatment group were
separated on a NuPageH 4–12% Bis-Tris gel (Invitrogen) and
electrotransferred to Immobilon P membrane (Millipore, Bedford,
MA) at 30 V for 1.5 hr. Membranes were blocked in 5% milk
TBST and labeled overnight at 4uC with primary antibody CT20
against C-terminal domain of APP (gift from Pritam Das, Mayo
Clinic Florida). Blots were incubated with HRP-linked secondary
antibody for 1 hour (Invitrogen), and protein bands were detected
using Western LightningHPlus-ECL (Perkin Elmer). Equivalent
sample loading was confirmed by probing the blots with the anti-
GAPDH antibody (Pierce/Thermo Scientific).
Immunocytochemistry
The intracellular localization of LRRTM3, APP and BACE1
was assessed in our SH-SY5Y-APP695wt monoclonal cell line,
which was transfected with pCMV vector expressing a full length
human LRRTM3 construct with a V5 tag, with or without co-
transfection with a human full length BACE1 construct with an
influenza hemagglutinin (HA) tag, also expressed within a
pcDNA3 vector. Cells were seeded onto poly-D lysine coated
cover slips, grown in Opti-MEM with 10% fetal bovine serum and
transfected with Lipofectamine 2000 (Invitrogen) 24 hours after
plating. Four hours post-transfection, the media was removed and
replaced with fresh media containing 2 ml/ml baculovirus
BacMam 2.0 (Invitrogen) expressing a GFP-tagged protein specific
for one of the following organelles (targeted protein, catalog
number): Early Endosomes-GFP (Rab5a, C10586, Invitrogen
CellLightHReagents), Golgi-GFP (N-acetylgalactosaminyltransfer-
ase 2, C10592) or Lysosomes-GFP (lysosomal associated mem-
brane protein 1, O36228). After 24 hours, the cells were fixed in
4% paraformaldehyde, permeabilized, and blocked for 1 hr in 5%
milk/PBS. Following incubation of primary antibody for 1 hour,
cells were washed and incubated in conjugated secondary
antibody for 1 hour. The following primary/secondary antibodies
were used: LRRTM3: anti-V5/red Alexa Fluor 594 goat anti-
mouse (double stains) or red Alexa Fluor 568 donkey anti-mouse
(triple stains); BACE1: anti-HA/magenta Alexa Fluor 647 goat
anti-rabbit; APP: CT-20/green Alexa Fluor 488 goat anti-rabbit
(double stains) or magenta Alexa Fluor 647 goat anti-rabbit (triple
stains); organelles: GFP fluorescence. All antibodies were from
Invitrogen, except CT20. All antibodies were diluted 1:1000 in
5% milk/PBS, except, CT20 which was diluted 1:250.
We also performed confirmatory experiments for early
endosomal localization of LRRTM3, by transfecting the SH-
SY5Y-APP695wt cells with pcDNA6.2 vector expressing a full
length human LRRTM3 construct with a GFP tag, and using an
alternative endosomal stain with EEA1 (early endosome antigen 1)
antibody 1:1000 (BD Transduction 610456) and Alexa Fluor 568
donkey anti-mouse 1:1000 (Invitrogen A10037; red) secondary
antibody.
Nuclei were stained with DAPI (Molecular Probes). Immuno-
stained cells were mounted using Fluoromount-G (SouthernBio-
tech) and imaged using the Zeiss LSM510 Laser Scanning Meta
confocal microscope. The distribution of APP and LRRTM3 in
neurons were detected by assessment of primary cortical neuronal
cultures that were prepared from Tg2576 mice that expresses the
Swedish mutant of APP (APPK670N,M671L) at high levels in the
brain [18]. Primary cortical neuronal cultures were prepared from
P2 mice and plated onto poly-D lysine coated cover slips, which
were maintained in neurobasal media containing 2% B27
supplement, 2mM glutamine and gentamicin. To ensure robust
transgene expression, we used an adeno-associated virus (rAAV1)
mediated neuronal transduction method [19,20]. We generated a
viral construct expressing a human full-length LRRTM3 cDNA
(NM_178011) with a V5 tag at the amino terminus. Neuronal cells
were transduced at day 7 at a viral titer of 7.561011 gc/mL. After
an additional 2 days, cells were fixed in 4% paraformaldehyde,
washed and then permeabilized with 0.2% Triton X-100.
Neuronal cultures were incubated for 1 hour with primary
antibodies V5 (Sigma; 1:1000) to detect LRRTM3 and CT20
(1:250) to detect APP, washed and then incubated with green
Alexa Fluor 488 goat anti-mouse and red Alexa Fluor 594 goat
anti-rabbit secondary antibodies to visualize LRRTM3 and APP,
respectively. Images were acquired with the Zeiss LSM510 Laser
Scanning Meta confocal microscope.
Co-immunoprecipitation (co-IP) Experiments
Cultured human embryonic kidney HEK293T cells were grown
for 24 hours (hrs) on 10 cm plates to 70% confluency and then
transfected using Lipofectamine 2000 (Invitrogen) with the
indicated expression constructs. Transfection media was removed
after 4 hrs and replaced with fresh Opti-Mem with 10% FBS.
After an additional 24 hrs the cells were harvested and lysed in IP
buffer (150mM NaCl, 50mM Tris pH 7.5, 0.1% Triton) and total
protein concentration was determined for each lysate. Immuno-
precipitation (IP) protocol was then followed according to the
manufacturer’s instructions (Immunoprecipitaion Kit- Dyna-
beadsHProtein G (100.07D Invitrogen)). Briefly 1ug of either V5
Invitrogen P/N46-1157 (LRRTM3), GFP abcam ab6556
(BACE1) or CT20 (APP) antibody was bound to Dynabeads
Protein G and incubated for 30 minutes with the protein lysate
before being extensively washed. Additional IgG, IgM controls
were included to ensure lack of non-specific binding of protein
complexes. Eluted immunocomplexes were resolved on a 4–12%
NuPage Bis-Tris gel (Invitrogen) and Western blot assays
performed with the indicated primary antibody (1:3000 dilution)
and appropriate HRP conjugated secondary antibody (1:3000
dilution/Invitrogen anti-rabbit NIF824,anti- mouse NIF825).
Gene Expression Studies
In-vitromodel. H4 human neuroglioma cells overexpressing
wild type APP were transfected with three different anti-LRRTM3
siRNAs discussed above or si-control. Twenty-four hours post-
transfection, total RNA extracted from harvested cells and was
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submitted to quantitative PCR (qPCR) to measure levels of
LRRTM3 (Hs01060657_m1), BACE1 (Hs01123242_m1),
CTNNA3 (Hs00203156_m1) and APP (Hs01552283_m1). Con-
trol genes were also measured (Hs99999905_m1=GAPDH;
Hs02800695_m1=HPRT). TaqMan chemistry was utilized for
the qPCR assays. Each experiment was replicated 2–6 times and
measured in quadruplicate. All expression levels were normalized
to HPRT. Expression levels relative to one of the replicates for the
si-control treatment were calculated. The difference in these
relative expression levels for each gene between the treatment
groups was evaluated by Kruskall-Wallis test in StatsDirect
(v2.7.8).
Human brains. Human brain expression levels for
LRRTM3, BACE1, CTNNA3, APP and control genes were obtained
from an autopsied cohort which was assessed in a recently
published brain expression GWAS (eGWAS), where the method-
ology is described in detail (eGWAS) [21,22]. Briefly, expression
levels of 24,526 transcripts were measured from the cerebellum
and temporal cortex of autopsied brains from subjects with
pathologic AD (cerebellar n = 197, temporal cortex n= 202) and
those with other brain pathologies (non-AD, cerebellar n= 177,
temporal cortex n= 197). Total RNA extraction and QC were
done using the Ambion RNAqueous kit and Agilent 2100
Bioanalyzer, respectively, according to published methods. Whole
genome DASL expression microarrays (Illumina, San Diego, CA)
were used for the transcriptome measurements of RNA samples
that were randomized across chips and plates using a stratified
approach to ensure balance with respect to diagnosis, age, sex,
RNA Integrity Numbers (RIN) and APOE genotype. Raw probe-
level expression data exported from Genome Studio software
(Illumina Inc.) were preprocessed with background correction,
variance stabilizing transformation, quantile normalization and
probe filtering using the lumi package of BioConductor (Du et al.,
Bioinformatics, 2008; Lin et al., Nucleic Acid Res, 2008).
Preprocessed probe transcript levels were used in the downstream
analysis. The following probes were analyzed: LRRTM3
(ILMN_2053334), CTNNA3 (ILMN_2131732), BACE1
(ILMN_2320349), APP (ILMN_2404063). All four probes had
signals detectable above background for .75% of the samples
from both brain regions and all diagnostic categories, with the
exception of CTNNA3, which was detectable in 50–75% of the
cerebellar samples.
Multivariable linear regression analyses were conducted, where
expression levels for LRRTM3 were used as the covariate, and
those for the other gene were used as the dependent variable.
Additional covariates that were utilized to correct for technical or
biological variables include APOE e4 dosage, age at death, sex,
PCR plate, RIN, (RIN-RINmean)2, as well as expression levels of
genes that are specific for the main five cell types present in the
central nervous system (CNS), namely ENO2 for neurons
(ILMN_1765796), GFAP for astrocytes (ILMN_1697176), CD68
for microglia (ILMN_2267914), OLIG2 for oligodendrocytes
(ILMN_1727567) and CD34 for endothelial cells
(ILMN_1732799). These 5 expression levels were included to
account for neuronal loss, gliosis and/or vascular tissue in the
assessed brain regions. All analyses were done for the cerebellar
and temporal cortex gene expression levels, separately. All analyses
were conducted in the combined AD and non-AD subjects, where
AD diagnosis was included as a covariate. The statistical package
StatsDirect was utilized for the multivariable linear regression
analyses (v2.7.8).
LRRTM3 knock-out mice brains. We obtained LRRTM3
knock-out mice from the the Mutant Mouse Regional Resource
Center (MMRC). The mouse strain used for this research project,
B6;129S5-Lrrtm3tm1Lex/Mmcd, identification number 032451-
UCD was donated to the MMRRC by Genentech, Inc. Mouse
hemibrains from LRRTM3 knock-out, heterozygote and wild type
animals were subjected to total RNA extraction using PureLink
RNA Mini Kit Ambion, followed by qPCR to measure levels of
endogenous mouse brain LRRTM3 (Mm00618457_m1), BACE1
(Mm00478664_m1), CTNNA3 (Mm00617137_m1), APP
(Mm01344172_m1), in addition to other LRRTMs
(LRRTM1=Mm00551337_g1, LRRTM2=Mm00731288_s1)
and control genes (GAPDH=Mm99999915_g1,
HPRT=Mm0046968_m1). TaqMan chemistry was utilized for
the gene expression assays. Control genes were used for
normalization of gene expression levels. Three animals were used
per each LRRTM3 genotype, and each brain expression assay was
done in quadruplicate. Mice brains were obtained at post-natal
day 4 (P4) and also at ,5.3 months of age. Endogenous mice Ab
ELISAs were done at P4 using mice hemibrains.
Genetic Association Studies
Subjects and samples. Unrelated subjects from six inde-
pendent LOAD case–control series, consisting of Caucasians with
an age-at-diagnosis (LOAD), evaluation (elderly controls) or death
(autopsy series) $60 years, were utilized in this study
(3,166 LOAD vs. 3,261 controls; Table S1 in File S1). Three
series were genotyped and analyzed for all of the SNPs as the
exploratory cohort (Cohort 1). Cohort 1 series were collected at
Mayo Clinic in Jacksonville, Florida (JS: 591 LOADs, 593
controls), Rochester, Minnesota, (RS: 553 LOADs, 1,374 controls)
and an autopsy-confirmed series from the Brain Bank at Mayo
Clinic Florida (AUT: 576 LOADs, 363 controls). The replication
cohort (Cohort 2) consisted of subjects from the National Cell
Repository for Alzheimer’s Disease [22] (NCRAD: 702 LOADs,
209 controls), Caucasian series from Poland [23] (PS: 483 LOADs,
189 controls), and from Norway [24] (NW: 261 LOADs, 533
controls). All clinical LOAD subjects had a diagnosis of probable
or possible AD and all autopsied LOAD subjects of definite AD
made according to NINCDS-ADRDA criteria [25]. All controls
from the clinical Caucasian-American series had a clinical
dementia rating score of 0. All autopsied LOAD brains had
Braak scores of $4.0. Brains employed as controls had Braak
scores of #2.5 but most had pathologies unrelated to AD that
included vascular dementia, frontotemporal dementia, dementia
with Lewy bodies, multi-system atrophy, amyotrophic lateral
sclerosis, and progressive supranuclear palsy [26]. The autopsy
cohort, which includes these non-AD control subjects with other
pathologies have been utilized in other AD genetic association
studies, including the Mayo LOAD risk GWAS [26], where it
yielded results similar to the clinical LOAD case-control series.
Nonetheless, it is theoretically possible that AD risk variants that
also influence some of the other non-AD pathologies may not be
picked up in this cohort, potentially leading to false-negatives. All
DNA samples were isolated from peripheral blood, with the
exception of samples in the autopsy series where DNA was isolated
from donated brain tissue, as described in previous publications
[22,23,24]. This study was approved by the appropriate institu-
tional review board and appropriate informed consent was
obtained from all participants.
SNP genotyping. Sixty-nine SNPs encompassing the region
from the 59 untranslated region (59 UTR) of LRRTM3 to its 39
UTR were genotyped using either the Sequenom platform
(Sequenom Inc., San Diego, CA, USA) [27] or TaqManH SNP
Genotyping Assay (Applied Biosystems, Foster City, CA). All
variants had Hardy-Weinberg disequilibrium p values .0.0001 in
controls, minor allele frequencies of .0.01 and genotyping rates
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.90% in each of the tested cohorts. All 69 SNPs were genotyped
in the exploratory Cohort 1. The eight SNPs that constitute
haplotype block 1, which form multilocus genotypes (MLGs) with
suggestive global LOAD risk association in this cohort, were also
genotyped in Cohort 2.
Statistical analysis. Single SNP analyses were done within
PLINK [28] using logistic regression approach and an additive
model, controlling for age at diagnosis/evaluation/death, sex,
APOE4 dosage (0, 1, 2) and series. Each cohort was assessed
individually and then jointly. Haplotype blocks were determined
using the solid spine of linkage disequilibrium (LD) approach
within Haploview program [29] and the SNP genotypes for all
69 SNPs from Cohort 1 series. The SNP haplotypes for this cohort
were submitted to association analyses with LOAD risk using an
additive model, and controlling for the covariates above, within
Haplo.Stats [30]. Multilocus genotype analyses (MLGs) were done
as previously described [31]. MLGs are defined by the combina-
tion of minor allele counts at all of the SNP loci, where each locus
has 0, 1 or 2 minor alleles. Use of MLGs allows assessment of the
genotypes at multiple SNP loci in a combined fashion and does not
depend on individual haplotype estimations. After determination
of the MLGs for SNPs within each LD block, for each subject,
association with LOAD risk was tested. The MLGs within each
LD block were tested by inclusion in a logistic regression model,
where each subject gets a ‘‘10 for the MLG that they have and ‘‘00,
otherwise. The most common MLG is used as the reference group.
Age, sex, APOE4 dosage and series were again included as
covariates. MLGs for SNPs within all LD blocks, except 1, were
genotyped in Cohort 1 only. Those in LD block 1 were tested
separately for Cohorts 1 and 2, as well as jointly. An additional
MLG association analysis for block 1 SNPs was also conducted for
all USA-Caucasian series (i.e. JS, RS, AUT, NCRAD). The p
values and odds ratios (ORs) of association for each MLG as well
as global significance for the model including all MLGs were
determined within the StatDirect statistical package. Global
significance was detected by comparison of the full model,
including all covariates and MLGs to the model that only includes
the covariates, where the difference between the chi squared test
statistic based on the deviance likelihood ratios and degrees of
freedom between the two models, were used to obtain the global p
values for the MLGs.
Results
LRRTM3 Knock-down by siRNA Decreases BACE1
Processing Products of APP
Human neuroblastoma SH-SY5Y cells with stable overexpres-
sion of wild type APP (SH-SY5Y-APP695wt) were transfected with
either anti-LRRTM3 siRNA (si-LRRTM3, SA-
SI_Hs01_00163676, Sigma) or control (si-control, SIC001 MIS-
SION Universal Negative Control#1, Sigma). The harvested
media was assessed by ELISA measurements of Ab40, Ab42,
sAPPa and sAPPb and protein harvested from cells was analyzed
for APP by Western blot analysis. Ab40 levels were significantly
lower in the si-LRRTM3 (mean6SEM=441.0 fmol/ml 68.5) vs.
si-control (528.1 fmol/ml 69.1) treated group (p = 0.03). Similar-
ly, Ab42 levels were also significantly lower in the si-LRRTM3
(173.0 fmol/ml 67.4) vs. si-control (235.0 fmol/ml 66.7) groups
(p = 0.03). The secreted N-terminal BACE1 cleavage product of
APP, sAPPb, was also decreased significantly in the si-LRRTM3
(6667.7 pg/ml 6246.7) vs. si-control (8069.7 pg/ml 6576.1)
group (p = 0.03). There was, however no difference in the a-
secretase N-terminal cleavage product of APP, sAPPa, in the si-
LRRTM3 (553.1 ng/ml 627.2) vs. si-control (577.6 ng/ml
624.3) groups (p = 0.9). Likewise, APP levels did not show any
difference on Western blot analysis of the two groups.
LRRTM3, APP and BACE1 Co-localize in Early Endosomes
SH-SY5Y-APP695wt cells transiently transfected with
LRRTM3 were transduced with baculovirus that expresses a
fusion protein of an organelle marker and GFP. LRRTM3 co-
localizes with the early endosomal marker (Figure 1, Figure S3),
but not with lysosomes (Figure S4) or Golgi apparatus (Figure
S5). When these cells were also stained for APP, co-localization of
LRRTM3 and APP in punctate intracellular structures
(Figure 1a, Figure S6), which also express the early endosomal
marker is evident. APP also localizes within early endosomes
(Figure 1a, Figures S7–S8), which is consistent with the
literature [32].
Likewise, SH-SY5Y-APP695wt cells with transient transfection
of both LRRTM3 and BACE1 and expressing the early
endosomal marker, reveal localization of BACE1 to early
endosomes (Figure 1b), which is known [32], as well as co-
localization of LRRTM3 and BACE1 within early endosomes.
Finally, primary cortical neuronal cultures from Tg2576 mice
expressing the Swedish mutant form of APP in the brain [18],
were transduced with rAAV1 expressing human full-length
LRRTM3 with V5 tag and stained for both LRRTM3 and APP
(Figure 1c). The rationale for using Tg2576 mice is to enable
assessment of neuronal co-localization of human APP with human
LRRTM3. We determined that human LRRTM3 and APP co-
localize in both the cell body and neuronal processes in these
primary neuronal cultures.
Co-immunoprecipitation (Co-IP) of LRRTM3, APP and
BACE1
To determine whether there is a biochemical interaction
between LRRTM3, APP and BACE1 we co-transfected
HEK293T cells with constructs expressing LRRTM3-V5 and
BACE1-GFP (Figure 2). The transfection conditions (Figure 2a)
and input amounts of each of the three proteins (Figure 2b) are
shown. We performed IP with either anti-V5 (Figure 2c), anti-
GFP (Figure 2d) or CT20 (anti-APP, Figure 2e), and as
expected, detected strong LRRTM3 or BACE1 signals where
these constructs were transfected and IP’ed, as well as endogenous
APP expression for all conditions.
When the eluted immunocomplexes from the IP with LRRTM3
were probed for BACE1 or APP, it was evident that both proteins
co-IP’ed with LRRTM3 (Figure 2c). Similarly, LRRTM3 could
be detected from the immunocomplexes that were IP’ed for
BACE1 (Figure 2d) or for endogenous APP (Figure 2e).
Gene Expression Studies
To investigate whether the siRNA knock-down of LRRTM3
influenced expression levels of BACE1, APP or its catenin
counterpart CTNNA3, we tested the three LRRTM3 siRNAs and
the control siRNA in H4 cells that stably overexpress wild type
APP and measured expression levels of these genes. LRRTM3
siRNA_1 (SASI_Hs02_00369484) and siRNA_3 (SA-
SI_Hs01_00163676) clearly led to knock-down of this gene.
LRRTM3 expression results for siRNA_2 (SASI_Hs01_00163674)
treatment experiments had a larger standard deviation precluding
this conclusion (Figure 3, Table S2 in File S1). Nonetheless, all
three LRRTM3 siRNAs had a knock-down effect observed in the
Westerns (Figure S1), although siRNA_3 had the biggest effect
(Figure 3, Figures S1–S2, Table S2 in File S1). Testing of
differences between the different treatment groups by Kruskall-
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Wallis non-parametric test revealed significant differences for
LRRTM3 gene expression levels (p = 0.016). We observed knock-
down of BACE1 and increase in CTNNA3 expression levels, the
trends of which were consistent especially for the siRNA_1 and
siRNA_3 knocked-down LRRTM3 levels. Significant treatment-
group effects were observed for BACE1 (p = 0.006) and CTNNA3
(p = 0.004), but not for APP gene expression (p = 0.9).
We next investigated correlations between brain expression of
LRRTM3 and those of the same three genes, BACE1, APP and
CTNNA3, using expression levels from ,400 human brains
utilized in our eGWAS [22]. All analyses were done while
correcting for technical and biological variables, as well as for
expression levels of genes that are specific for the five cell types
present in the CNS, as described in the Methods. Interestingly,
LRRTM3 and CTNNA3 levels are negatively correlated in the
temporal cortex (p,0.0001, b=20.24) similar to the trend in H4
cells, but show positive correlations in the cerebellum (p= 0.006,
b=0.18) (Table 1, Figure S9). Like the H4 cells, LRRTM3 and
BACE1 levels are positively correlated in the cerebellum
(p= 0.0003, b=0.11), but do not show significant association in
the temporal cortex (p = 0.27, b=0.02). Since BACE1 levels were
found to be higher in the temporal cortex of AD brains compared
to non-ADs [33], any potential associations between LRRTM3 and
BACE1 levels may be obscured in the AD temporal cortex. Indeed,
Figure 1. Co-localization of LRRTM3 and a) APP in early endosomes, b) BACE1 in early endosomes, c) APP in primary neurons. For a
and b, SH-SY5Y-APP695wt cells were transduced with baculovirus expressing fused early-endosomal protein Rab5a and GFP. These cells were
transfected with LRRTM3-V5 (a and b) and also with BACE1-HA (b). Results of staining with GFP fluorescence indicative of Rab5a expression (early
endosomes, green); anti-V5 (LRRTM3, red); and either CT20 in a (APP, magenta) or anti-HA in b (BACE1, magenta) are shown with overlay of the three
stains in the last panels of a and b. Co-localization of APP, LRRTM3 and early endosomes is visualized as white punctate intracellular structures in the
last panel of a(arrow and arrowhead). Co-localization of APP, BACE1 and early endosomes is visualized as white punctate intracellular structures in the
last panel of b. (Magnification:663). For c, primary neuronal cultures from Tg2576 transgenic mice transduced with rAAV-LRRTM3-V5 were stained
with anti-V5 (LRRTM3, green) and CT20 (APP, red). Overlay of the two stains reveals co-localization of LRRTM3 and APP visualized as yellow puncta in
the cell body (thin arrow) and neuronal process (thick arrow). (Magnification:6100).
doi:10.1371/journal.pone.0064164.g001
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when we repeated our analyses only in the non-AD brains,
LRRTM3 showed positive correlations in the temporal cortex of
this subset, as well (p = 0.02, b=0.07, 95%CI= 0.01–0.13), but
not in the ADs (p= 0.7). LRRTM3 and APP brain levels showed
strong positive correlations in both temporal cortex (p,0.0001,
b=0.15) and the cerebellum (p,0.0001, b=0.24), with similarity
in the effect sizes between these two independent brain regions.
There were two other probes for APP (ILMN_1653283 and
ILMN_2404065), both of which showed significant positive
correlations in the cerebellum and temporal cortex, except
ILMN_2404065, which was not significant (p = 0.21) but had a
positive trend in the temporal cortex (b=0.04).
Finally, we assessed endogenous mouse brain expression levels
of LRRTM3, BACE1, CTNNA3, APP and the other LRRTMs
(LRRTM1, LRRTM2 and LRRTM4) in LRRTM3 knock-out (ko),
heterozygote and wild type mice (Figure 4). We observed the
expected ,50% reduction of brain LRRTM3 in the heterozygote
and the absence of LRRTM3 in the ko mice (p = 0.04), but there
Figure 2. Co-IP of BACE1 and endogenous APP with LRRTM3 in HEK293T cells. LRRTM3-V5 and BACE1-GFP were transfected into HEK293T
cells as shown in (a) and as in inputs (b). Protein lysates from these cells and negative controls without overexpression were immunoprecipitated
using c. anti-V5 (LRRTM3), d. anti-GFP (BACE1) or c. CT20 (APP) antibodies. In the IP with anti-V5 (c), Western blot assays using anti-GFP or CT20,
demonstrate co-IP of BACE1 and endogenous APP with LRRTM3. Similarly, LRRTM3 staining is clearly demonstrated in IPs for BACE1 (d) and for APP
(e), indicating reverse co-IP of LRRTM3 with both proteins. Presence (+) or absence (2) of each of the three proteins for the depicted experiments are
shown in (a) for each of the experimental conditions within the four lanes. Antibodies used in the Western blots are listed to the right of each figure.
Proteins that are IP’ed or co-IP’ed are shown to the left of each figure.
doi:10.1371/journal.pone.0064164.g002
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were no differences in the levels of any of the other tested genes at
either P4 (Figure 4, Table S3 in File S1) or the later 5.3 month
timepoints (data not shown). There were no differences in the P4
mouse brain endogenous Ab40 or Ab42 levels of the mice from
the three LRRTM3 genotypic groups (data not shown).
Association of Genetic Variants at the LRRTM3 Locus with
LOAD Risk
Single SNP analysis of 69 SNPs at the LRRTM3 locus in the
exploratory Cohort 1 composed of 1,720 ADs and 2,330 controls
(Table S1 in File S1) revealed that none of the SNPs were
significantly associated with LOAD risk after corrections for
multiple testing (Table S4 in File S1). Haplotype analysis
likewise did not reveal any significant associations (Table S5 in
File S1). There were 7 haplotype blocks of SNPs in LD (Figure
S10). Analysis of MLGs in Cohort 1 showed suggestive LOAD risk
association for the multilocus SNP genotypes for LD block 1
variants (p = 0.06, Table 2, Tables S5, S6 in File S1)
encompassing 59UTR-Intron 1 regions of LRRTM3, but not for
any of the MLGs in the other blocks. The SNPs in LD block 1
(Figure S10) were therefore genotyped and assessed in the
replication Cohort 2 (1,446 ADs and 931 controls, Table S1 in
File S1). Though they did not achieve significance in this
replication cohort (p = 0.55), when Cohorts 1 and 2 were jointly
assessed (3,166 LOAD and 3,261 controls), the global MLG
association was significant (p = 0.036), with three MLGs achieving
nominal significance (p,0.05) and five others that are suggestive
Figure 3. Relative expression levels of genes in H4 cells treated with three anti-LRRTM3 and a control siRNA. Bar graphs depicting mean
relative gene expression levels and error bars representing the standard deviations obtained from the averages of 2–6 experiments where each
experiment is assessed in quadruplicate. Relative expression values are obtained by the delta delta Ct method, where HPRT is utilized as the control
gene (delta Ct) and all results are normalized to one of the control wells (delta delta Ct). Relative expression values (2ˆ(-delta delta Ct)) are plotted on
the y-axis. The different siRNA treatment groups are color-coded as shown in the inset. The genes with expression level measurements are shown in
groups, with gene names depicted on the x-axis.
doi:10.1371/journal.pone.0064164.g003
Table 1. Human brain expression correlations between levels of LRRTM3, and CTNNA3, BACE1 or APP.
Outcome Variable Covariate Temporal cortex Cerebellum
P Beta 95%CI P Beta 95%CI
ILMN_2131732_CTNNA3 ILMN_2053334_LRRTM3 ,0.0001 20.24 20.36 20.13 0.006 0.18 0.05 0.30
ILMN_2320349_BACE1 0.27 0.02 20.02 0.07 0.0003 0.11 0.05 0.17
ILMN_2404063_APP ,0.0001 0.15 0.11 0.20 ,0.0001 0.24 0.16 0.32
Multivariable linear regression analyses were conducted while controlling for technical variables (plate, RIN), biological variables (diagnosis, age, sex, APOE4 dose) and
variables accounting for cell loss, gliosis and vascularity by including as covariates expression levels of genes highly expressed in neurons (ENO2), astrocytes (GFAP),
oligodendrocytes (OLIG2), microglia (CD68) and endothelial cell (CD34). The brain levels of CTNNA3, BACE1 or APP were used as the outcome variable in a model, which
included the above covariates and LRRTM3 brain expression levels. Gene expression levels were detected in both the temporal cortex and cerebellum, for which results
are shown separately. The significance (p), effect size (Beta) and 95% confidence interval of the effect size (95%CI) of LRRTM3 expression for each of the tested genes are
shown. Significant results are highlighted. Negative beta reflects an inverse relationship and positive correlation have a positive beta.
doi:10.1371/journal.pone.0064164.t001
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(0.05,p,0.2). To investigate whether the presence of three series
with different countries of origin in Cohort 2 could have led to
decreased level of significance, secondary to potential increase in
heterogeneity, we also investigated MLG association for LD block
1 variants in just the series from the USA (Table 1, Table S4 in
File S1). Indeed, global MLG association was slightly better in the
Caucasian-USA series (p = 0.02) despite smaller sample size (2,422
LOADs and 2,539 controls) than combined cohorts 1+2. Eight
MLGs showed significant or suggestive LOAD risk association in
the Caucasian-USA series, seven of which overlapped with the
combined Cohort 1+2 analysis and five of which has improved
significance. We note that while none of the individual MLGs
would be significant after correcting for 31 tested MLGs, the
global MLG associations do not require such a correction, so
global p,0.05 is statistically significant.
Discussion
In this study we investigate functional and genetic role of
LRRTM3 in AD risk. In our functional studies we demonstrate
co-localization of LRRTM3, APP and BACE1 in early endosomes
of human neuroblastoma cells; co-localization of LRRTM3 and
APP in cell body and processes of primary neurons from Tg2576
mouse model [18] and co-IP of LRRTM3 with BACE1 and
endogenous APP from HEK293T cells. We also confirm the prior
results of decreased BACE1 cleavage products of APP in the
setting of anti-LRRTM3 siRNA treatment of SH-SY5Y-
APP695wt cells [4]. Unlike the original report, however, we find
significant decrease of BACE1 mRNA, upon treatment with
siRNAs against LRRTM3. The discrepancy between our LRRTM3
siRNA results in regards to lowering of BACE1 levels and the
Majercak et al. study [34], which did not observe any changes in
BACE1 levels upon lowering of LRRTM3 could be due to several
reasons. It is possible that technical differences could account for
this: we utilized different siRNAs, evaluated expression changes in
different cell types, utilizing different gene expression measure-
ment approaches. It could be argued that the influence on BACE1
of the LRRTM3 siRNAs we utilized is an artifactual, off-target
effect. We think this is unlikely, since we observe this effect with at
least two of three siRNAs. Further, the positive correlations we
detected between human brain levels of LRRTM3 and BACE1
raise the possibility that the levels of these genes might be co-
regulated, although the correlations alone would not be sufficient
for a definitive conclusion. Our findings suggest that the Ab-
lowering effect of LRRTM3 knock-down in our in-vitro model,
might be secondary to concurrent knock-down of BACE1, whereas
Majercak et al. concluded that decreased LRRTM3 levels might
influence vesicle trafficking or signaling. In reality, more than one
mechanism might be at play.
Indeed, we also observe significant increases in the a-catenin
counterpart of LRRTM3, namely CTNNA3, upon knocking down
of LRRTM3 in-vitro, which was not previously reported. The strong
negative correlations of human brain CTNNA3 and LRRTM3
levels in the temporal cortex, is also consistent with the in-vitro
knock-down results. Intriguingly, these negative correlations are
only observed in the temporal cortex, which is the primarily
affected region in AD, but in the cerebellum, which is an AD-
unaffected region, strong positive correlations are observed
between levels of these two genes. It is hypothesized that
transcriptional regulation of nested genes may lead to either
positive or negative correlations between gene levels, which might
imply similar or diverse functions for the genes, respectively [35].
Investigation of the LRRTM2/CTNNA1 and LRRTM1/CTNNA2
Figure 4. Expression levels of genes in brains of Lrrtm3 knock-out, heterozygote and wild type mice. Bar graphs depicting mean gene
expression levels and error bars representing the standard deviations obtained from the averages of 3 animals per genotypic group where expression
levels from each mouse brain is assessed in quadruplicate. Expression values are obtained by the delta Ct method, where geometric mean of HPRT
and GAPDH is utilized as the control gene expression values. Average expression values (2ˆ(-delta Ct))x100 were plotted on the y-axis. The three
mouse genotypic groups are color-coded as shown in the inset. The genes with expression level measurements are shown in groups, with gene
names depicted on the x-axis.
doi:10.1371/journal.pone.0064164.g004
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pairs identified a common promoter with bi-directional transcrip-
tion, which resulted in truncated CTNNA1 and CTNNA2 that
are highly expressed in the CNS [36]. Collectively, these results
underline the potential that changes in LRRTM3 levels might also
influence CTNNA3 levels and that any downstream effects (such as
those on Ab metabolism) could be due to one or both of these
genes. Although direct knock-down of CTNNA3 did not influence
Ab levels in the Majercak et al. study, levels of CTNNA3 were not
evaluated in the LRRTM3 knock-down model.
Our immunohistochemistry and biochemistry results suggest
that APP, BACE1 and LRRTM3 co-localize to early endosomes
and also have biochemical interactions. We acknowledge that
these studies were conducted in paradigms where LRRTM3 was
overexpressed due to lack of a robust antibody despite testing five
different commercial antibodies and generating one ourselves
(Supplementary Methods in Text S1). It is therefore theoretically
possible that overexpression of LRRTM3 could have led to
mislocalization. Despite this caveat, we have demonstrated not
only localization of LRRTM3 in early endosomes, but also its lack
of localization from lysosomes or Golgi apparatus. Furthermore,
we have been able to detect both co-localization and biochemical
interaction between endogenous APP with overexpressed
LRRTM3. Additionally, though BACE1 was also overexpressed,
we have been able to detect its appropriate localization to early
endosomes and expected interactions with APP. While further
studies are needed utilizing endogenous LRRTM3, our findings
provide evidence for the first time, for interactions between
LRRTM3, APP and BACE1. Interestingly, LRRTM3 and APP
levels show strong positive correlations in the human temporal
cortex and cerebellum. Given that the in-vitro studies with siRNA
against LRRTM3 did not yield any changes in APP levels, the
human brain transcriptome findings could imply an upstream
regulatory factor for both genes. Alternatively, high levels of
overexpressed APP in the in-vitro paradigm could mask any subtler
changes in APP levels upon manipulating LRRTM3 expression.
It should be noted that a recent study of Lrrtm3 knock-out mice,
by Laakso et al., did not identify any changes in either endogenous
Ab levels or processing of APP in mice crossed with the APP/PS1
mutant mice [37]. This finding is contradictory to the in-vitro
findings in our study and others [6,34]. One explanation is that all
of the in-vitro findings are artifactual and due to off-target effects of
siRNAs. While theoretically possible, given the observed effects on
APP processing in multiple different paradigms with different
siRNAs, alternative explanations also need to be considered. It is
plausible that the influence on APP metabolism might be a species-
specific function. Further, if the influence is secondary to
regulatory changes in other genes, including CTNNA3, this
regulatory machinery could differ between humans and mice.
Indeed, unlike the findings in our in-vitro studies conducted in
human-derived cells and human brain transcriptome, we did not
see any gene expression changes in App, Bace1 or Ctnna3 in brains
of Lrrtm3 knock-out mice, although we used a different mouse
strain than the Laakso et al. study [37]. Compensatory effects in
knock-out animals is also a concern. While compensatory changes
in other Lrrtms were not reported [37], it remains possible that
there could be downstream modifications in other untested genes
germaine to the APP metabolism. To further investigate the role of
LRRTM3 in APP metabolism, additional studies focused on
human cell lines and iPS cells are required. Further, thorough
characterization of transcriptional changes in Lrrtm3 knock-out
mice, additional mouse models characterizing human LRRTM3
and CTNNA3 both separately and jointly are warranted.
Our genetic analysis revealed association of multilocus geno-
types (MLG) in the 59UTR-Intron 1 region of LRRTM3 with AD
risk, marginally in the exploratory cohort, non-significant in the
follow-up cohort, though significant overall and individual MLG
associations in the combined cohort, supporting consistent trends
in the second cohort. These associations were even more
significant in the subset of Caucasian-American series, which
might be due to decreased heterogeneity of this cohort. The lack of
significant single SNP or haplotype associations, but significant
MLG associations may be due to the presence of multiple
functional genetic variants, interactions between alleles at the same
SNP and between variants or a combination of these factors.
Indeed, two other studies utilized the MLG approach with
LRRTM3 SNPs and showed association with AD risk. One study
identified 5 LRRTM3 SNPs, the MLGs of which formed three
clusters, wherein variants of PLAU, CDC2 and ACE showed
significant AD risk association [15]. Another study identified two
and three locus genotypes with SNPs in LRRTM3, ACE and A2M
that associate with AD risk [17]. These findings suggest the
presence of intreactions between variants at these genes, which
have biological implications in APP metabolism. Although, our
study only focused on MLGs within LRRTM3, our results can
similarly be interpreted as being influenced by variant interactions
at this region.
Our findings nominate the 59UTR-Intron 1 region of LRRTM3
(LD block 1) as having the most significant effect on AD risk. Two
other studies identified AD risk variants in this region. Rs1925583,
which showed significant AD risk association in APOE4 carriers
[8], though not significant in our study, resides within the
significant MLG block 1. Rs16923760, which associates with AD
risk in a Caribbean-Hispanic series (OR=0.74) [6], is in LD with
rs4746648 (D’ = 1.0, r2 = 0.01) that has nominally significant AD
risk association in our combined cohort (p = 0.02, OR=0.86).
Review of the individually significant MLGs does not lead to the
identification of specific variants with risky or protective effects.
This is likely to occur if there is heterogeneity, such that the SNPs
at this MLG block may be tagging both risky and protective
functional variants. Nevertheless, these results collectively suggest
the presence of variants in the 59UTR-Intron 1 region of
LRRTM3 and should serve as a guide in the search of functional
variation in this gene.
The LRRTM3 variants in MLG block 1 are not in any LD with
the top CTNNA3 (VR22) variants that associate with Ab levels [7]
and AD risk in some studies. This suggests independent roles for
these nested genes in AD. Any further possible functional and/or
genetic interaction between LRRTM3 and CTNNA3 (VR22)
remains to be elucidated.
In summary, our study identifies biochemical and immunocy-
tochemical interactions between LRRTM3, BACE1 and APP;
gene expression correlations between these genes and also
CTNNA3; confirms the effect of LRRTM3 siRNA on reducing
BACE1-cleavage products of APP and detects MLGs in the
59UTR-Intron 1 region of LRRTM3 that associate with AD risk.
Despite the strength of joint functional and genetic assessment of
this gene, and detailed fine-mapping of this region in two cohorts,
our study has some weaknesses. The co-localization experiments
were conducted in paradigms where all three proteins and the co-
IP experiments were done in models where LRRTM3 and
BACE1 are overexpressed. This is a potential concern with all
overexpression experiments, but may not be possible to avoid,
often due to lack of appropriate antibodies, as was the case in our
study. Nonetheless, the co-IP of endogenous APP with LRRTM3
and vice versa; the biologically consistent immunocytochemistry,
biochemistry and siRNA data; alongside the genetic results
provide collective support for a role of LRRTM3 in APP
metabolism. Another weakness is the lack of significant MLG
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association in the second cohort, although improved significance
in the combined cohorts 1+2 suggests consistent effects between
the first and second cohorts. While it is not possible to discern the
individual protective or risky variants from the MLG analysis, our
results pinpoint to the specific 59UTR-Intron 1 region of
LRRTM3 for further studies.
LRRTM3, an evolutionarily conserved member of a synaptic
protein family was also detected as a risk gene in autism [38],
raising the possibility of a potential role of this gene in the
neurodevelopment-neurodegeneration axis. There is significant
precedence to pursue additional functional and genetic investiga-
tions of LRRTM3. Our results advocate downstream mechanistic
studies that focus on interactions of LRRTM3 with APP, BACE1
and CTNNA3; and genetic studies that investigate the 59UTR-
Intron 1 of LRRTM3 for functional variants.
Supporting Information
Figure S1 Knock-down of LRRTM3 with different
siRNAs. SH-SY5Y cells with stable overexpression of LRRTM3
with a DDK tag (LRRTM3-DDK) were treated with three
different siRNAs against LRRTM3 (lanes 1–3), control siRNA
(lane 4) or not treated. Top and bottom panels show Western blot
assays for LRRTM3 (anti-DDK) and GAPDH, respectively. The
knock-down of LRRTM3 is evident with all three anti-LRRTM3
siRNAs, but not with the control siRNA. siRNAs in lanes 1–3 are
as follows in order: SASI_Hs02_00369484, SA-
SI_Hs01_00163674, SASI_Hs01_00163676.
(TIF)
Figure S2 Dose-dependent knock-down of LRRTM3.
The fold change of LRRTM3 levels in HEK293T cells are
expressed with respect to lipofectamine control. The average
normalized Ct values for each experimental group are utilized in
the analyses. There were two experiments per group and 4
replicates per experiment. The ,40% knock-down in LRRTM3
expression was detected for LRRTM3 siRNA SA-
SI_Hs01_00163676 amount of 40 pmols or greater.
(TIF)
Figure S3 Localization of LRRTM3 and early endo-
somes (example 2). SH-SY5Y-APP695wt cells were transfected
with LRRTM3-V5 and transduced with baculovirus expressing
fused early-endosomal protein Rab5a and GFP. Results of staining
with a. DAPI (nucleus); b. anti-V5 (LRRTM3); and c. GFP
fluorescence indicative of Rab5a expression (early endosomes); d.
overlay of a+b+c. There is abundant localization of LRRTM3
within the early endosomes. Magnification:6100.
(TIF)
Figure S4 Localization of LRRTM3 and lysosomes. SH-
SY5Y-APP695wt cells transfected with LRRTM3-V5 and trans-
duced with baculovirus expressing fused lysosomal protein Lamp1
and GFP. Results of staining with a. DAPI (nucleus); b. anti-V5
(LRRTM3); and c. GFP fluorescence indicative of Lamp1
expression (lysosomes); d. overlay of a+b+c. There does not
appear to be localization of LRRTM3 within lysosomes.
Magnification:6100.
(TIF)
Figure S5 Localization of LRRTM3 and Golgi appara-
tus. SH-SY5Y-APP695wt cells transfected with LRRTM3-V5
and transduced with baculovirus expressing fused Golgi apparatus
protein N-acetylgalactosaminyltransferase 2 and GFP. Results of
staining with a. DAPI (nucleus); b. anti-V5 (LRRTM3); and c.
GFP fluorescence indicative of N-acetylgalactosaminyltransferase
2 expression (Golgi); d. overlay of a+b+c. There does not appear to
be localization of LRRTM3 within the Golgi apparatus.
Magnification:6100.
(TIF)
Figure S6 Intracellular co-localization of LRRTM3 and
APP (example 2). SH-SY5Y-APP695wt cells were transfected
with LRRTM3. Results of staining with a. DAPI (nucleus); b.
CT20 (APP); and c. anti-V5 (LRRTM3); d. overlay of a+b+c.
There is abundant co-localization of LRRTM3 with APP.
Magnification:6100.
(TIF)
Figure S7 Co-localization of LRRTM3 and APP in early
endosomes (example 2). SH-SY5Y-APP695wt cells were
transfected with LRRTM3-V5 and transduced with baculovirus
expressing fused early-endosomal protein Rab5a and GFP. Results
of staining with a. DAPI (nucleus); b. GFP fluorescence indicative
of Rab5a expression (early endosomes); c. anti-V5 (LRRTM3);
d.CT20 (APP); e. overlay of a+b+c; f. overlay of a+b+d; g. overlay
of a+c+d; h.overlay of a+b+c+d. Co-localization of APP,
LRRTM3 and early endosomes is visualized as white punctate
intracellular structures in h and can also be seen in e-g. The two
cells stained for APP and not with LRRTM3 or early endosomes
clearly depict a different staining pattern than the cell in the
middle of the field, which stains with all three proteins.
Magnification:663.
(TIF)
Figure S8 Co-localization of LRRTM3 and APP in early
endosomes (example 3). Same conditions and staining are
used as Figure S5.
(TIF)
Figure S9 Simple linear regression plots for LRRTM3
vs. other gene brain expression level associations that
are significant in Table 1. Results for cerebellar expression
level plots are shown first followed by those for the temporal cortex
levels. The p values and correlation coefficients correspond to the
plots depicted above them.
(DOCX)
Figure S10 Linkage disequilibrium (LD) plot of 69 SNPs
at the LRRTM3 locus. Haploview 4.1 was utilized to obtain the
LD plot depicting D’ values for all SNP pairs, using genotypes
from Cohort 1. LD blocks are defined according to the solid spine
of LD algorithm. SNP names are depicted at the top of the figure.
Though, initially 71 SNPs were assessed, two SNPs which violated
Hardy-Weinberg equilibrium in controls from either cohort were
excluded from the analysis.
(TIF)
File S1 Includes Tables S1–S6.
(XLSX)
Text S1 Supplementary text.
(DOCX)
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